| GC33915-10mM(1mLinDMSO) |
|
52128-35-5 |
|
0 |
C19H23N5O3 |
|
|
|
| GC33914-100mg |
|
1258226-87-7 |
|
0 |
C50H67N7O8 |
|
|
|
| GC33914-50mg |
|
1258226-87-7 |
|
0 |
C50H67N7O8 |
|
|
|
| GC33914-10mg |
|
1258226-87-7 |
|
0 |
C50H67N7O8 |
|
|
|
| GC33914-5mg |
|
1258226-87-7 |
|
0 |
C50H67N7O8 |
|
|
|
| GC33914-10mM(1mLinDMSO) |
|
1258226-87-7 |
|
0 |
C50H67N7O8 |
|
|
|
| GC33912-10mg |
|
57378-72-0 |
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C)
|
0 |
C25H24O12 |
|
|
|
| GC33912-5mg |
|
57378-72-0 |
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C)
|
0 |
C25H24O12 |
|
|
|
| GC33912-10mM(1mLinDMSO) |
|
57378-72-0 |
4,5-Dicaffeoylquinic acid (Isochlorogenic acid C)
|
0 |
C25H24O12 |
|
|
|
| GC33911-100mg |
|
1375603-38-5 |
Seviteronel R enantiomer (VT-464 (R enantiomer))
|
0 |
C18H17F4N3O3 |
|
|
|
| GC33911-50mg |
|
1375603-38-5 |
Seviteronel R enantiomer (VT-464 (R enantiomer))
|
0 |
C18H17F4N3O3 |
|
|
|
| GC33911-10mg |
|
1375603-38-5 |
Seviteronel R enantiomer (VT-464 (R enantiomer))
|
0 |
C18H17F4N3O3 |
|
|
|
| GC33911-5mg |
|
1375603-38-5 |
Seviteronel R enantiomer (VT-464 (R enantiomer))
|
0 |
C18H17F4N3O3 |
|
|
|
| GC33911-2mg |
|
1375603-38-5 |
Seviteronel R enantiomer (VT-464 (R enantiomer))
|
0 |
C18H17F4N3O3 |
|
|
|
| GC33911-10mM(1mLinDMSO) |
|
1375603-38-5 |
Seviteronel R enantiomer (VT-464 (R enantiomer))
|
0 |
C18H17F4N3O3 |
|
|
|
| GC33910-100mg |
|
1159840-61-5 |
Gardiquimod trifluoroacetate
|
0 |
C21H25F6N5O5 |
|
|
|
| GC33910-50mg |
|
1159840-61-5 |
Gardiquimod trifluoroacetate
|
0 |
C21H25F6N5O5 |
|
|
|
| GC33910-25mg |
|
1159840-61-5 |
Gardiquimod trifluoroacetate
|
0 |
C21H25F6N5O5 |
|
|
|
| GC33910-10mg |
|
1159840-61-5 |
Gardiquimod trifluoroacetate
|
0 |
C21H25F6N5O5 |
|
|
|
| GC33910-5mg |
|
1159840-61-5 |
Gardiquimod trifluoroacetate
|
0 |
C21H25F6N5O5 |
|
|
|
